Form D — Claris Biotherapeutics, Inc.
0001809726-25-000004 · filed Sep 22, 2025
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $2,300,000
- Reported amount sold
- $2,300,000
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Claris Biotherapeutics, Inc.
- CIK
- 1809726
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- —
- Address
- 475 MAGELLAN AVE
HALF MOON BAY, California 94019 - Phone
- 201-344-7638
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Clarke Atwell · Executive OfficerJersey City, New Jersey Find on LinkedIn ↗
-
Reza Dana · DirectorJersey City, New Jersey Find on LinkedIn ↗
-
Kenneth Harrison · DirectorJersey City, New Jersey Find on LinkedIn ↗
-
Marc de Garidel · DirectorJersey City, New Jersey Find on LinkedIn ↗
-
Meredith Fisher · DirectorJersey City, New Jersey Find on LinkedIn ↗
-
Henry Rath · Executive OfficerJersey City, New Jersey Find on LinkedIn ↗
-
Susan Orr · Executive OfficerJersey City, New Jersey Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗